An investigation was recently published in the pages of the British Medical Journal,

outlining how Pfizer failed to disclose to pregnant women the risks that were potentially

present in their vaccine trials.

Specifically, quote, even though Pfizer knew about the potential safety signal and was studying

preterm births as an adverse event of special interest, it continued to enroll women in

its clinical trial and did not fully inform participants of the risks the vaccine may

pose to their babies, and in some cases provided misleading and contradictory statements.

Now, the vaccine in question here is for something known as RSV, and in case you've never

heard of it before, RSV, also known as respiratory syncytial virus, is essentially just another

name for the common cold.

Those include things like runny nose, sore throat, coughing, as well as a headache.

And what happened about two years ago, was that both Pfizer, as well as another company

called GlaxoSmithClient, which is one of the largest pharmaceutical companies in the

whole world, they were both developing an RSV vaccine that they were testing on pregnant

women.

However, what happened was that in February of last year, during phase three of their clinical

trial, GSK had to stop the trial over a possible increased risk of both premature births,

as well as neonatal deaths in vaccinated participants, which is, as you can imagine, a horrifying

prospect for pregnant women.

According to the investigation that was done by the British Medical Journal, quote,

immediately after becoming informed of the safety signal, GSK informed health authorities

and updated its consent forms.

...